Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four antimicrobial agents—amphotericin B, cefotaxime, polymyxin E (colistin), and tobramycin. Each component has a distinct mechanism of action:
This combination may be used for selective decontamination in critically ill patients or for managing severe infections involving multidrug-resistant organisms. The rationale behind such combinations includes broad-spectrum coverage against both fungal and resistant Gram-negative pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amphotericin B + cefotaxime + polymyxin E + tobramycin.